Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4

Hybridoma

Volumn 27, Issue 4, 2008, Pages 241-247

  Bandurska, Katarzyna ^a   Brodzik, Robert ^a   Spitsin, Sergei ^a   Kohl, Thomas ^a   Portocarrero, Carla ^a   Smirnov, Yuri ^a   Pogrebnyak, Natalia ^a   Sirko, Agnieszka ^b   Koprowski, Hilary ^a   Golovkin, Maxim ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTHRAX VACCINE; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOBACCO; TRANSGENIC PLANT; VIRUS LIKE AGENT;

ANIMALS; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; FEMALE; HEPATITIS B CORE ANTIGENS; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PLANTS, GENETICALLY MODIFIED; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TOBACCO;

BACILLUS ANTHRACIS; MUS; NICOTIANA TABACUM;

EID: 50249180248     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2008.0008     Document Type: Article

References (37)

1. Fox JL: Turning plants into protein factories. Nat Biotechnol 2006;24:1191-1193.
2. Gleba Y, Klimyuk V, and Marillonnet S: Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 2007;18:134-141.
3. Koprowski H: Vaccines and sera through plant biotechnology. Vaccine 2005;23:1757-1763.
4. Ma JK, Chikwamba R, Sparrow P, Fischer R, Mahoney R, and Twyman RM: Plant-derived pharmaceuticals - the road forward. Trends Plant Sci 2005;10:580-585.
5. Streatfield SJ: Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol J 2007;5:2-15.
6. Lobaina Y, Garcia D, Abreu N, Muzio V, and Aguilar JC: Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun 2003;300:745-750.
7. Pumpens P, and Grens E: HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001;44:98-114.
8. Santi L, Huang Z, and Mason H: Virus-like particles production in green plants. Methods 2006;40:66-76.
9. Schiller JT, and Lowy DR: Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 2001;1:571-581.
10. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, and Brown F: Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987;330:381-384.
11. Hildich CM, Rogers LJ, and Bishop DHL: Physicochemical analysis of the hepatitis B core antigen produced by a baculovirus expression vector. J Gen Virol 1990;71:2755-2759.
12. Huang Z, Santi L, LePore K, Kilbourne J, Arntzen CJ, and Mason HS: Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 2006;24:2506-2513.
13. Jean-Jean O, Levrero M, Will H, Perricaudet M, and Rossignol JM: Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen. Virology 1989;170:99-106.
14. Newman M, Suk FM, Cajimat M, Chua PK, and Shih C: Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J Virol 2003;77:12950-12960.
15. Kratz PA, Bottcher B, and Nassal M: Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999;96:1915-1920.
16. Seifer M, and Standring DN: Assembly and antigenicity of hepatitis B virus core particles. Intervirology 1995;38:47-62.
17. Borisova G, Arya B, Dislers A, Borschukova O, Tsibinogin V, Skrastina D, Eldarov MA, Pumpens P, Skryabin KG, and Grens E: Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J Virol 1993;67:3696-3701.
18. Chen X, Li M, Le X, Ma W, and Zhou B: Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. Vaccine 2004;22: 439-446.
19. Schödel F, Peterson D, Hughes J, Wirtz R, and Milich D: Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. J Biotechnol 1996;44:91-96.
20. Tindle RW, Herd K, Londono P, Fernando GJ, Chatfield SN, Malcolm K, and Dougan G: Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Virology 1994;200:547-557.
21. Zhang YL, Guo YJ, Wang KY, Lu K, Li K, Zhu Y, and Sun SH: Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus. Scand J Immunol 2007;65:320-328.
22. Huang Y, Liang W, Wang Y, Zhou Z, Pan A, Yang X, Huang C, Chen J, and Zhang D: Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. Viral Immunol 2005;18:668-677.
23. Mechtcheriakova IA, Eldarov MA, Nicholson L, Shanks M, Skryabin KG, and Lomonossoff GP: The use of viral vectors to produce hepatitis B virus core particles in plants. J Virol Methods 2006;131:10-15.
24. Chichester JA, Musiychuk K, de la RP, Horsey A, Stevenson N, Ugulava N, Rabindran S, Palmer GA, Mett V, and Yusibov V: Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007;25:3111-3114.
25. Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, Titball RW, and Williamson ED: A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002;70:1653-1656.
26. Brodzik R, Bandurska K, Deka D, Golovkin M, and Koprowski H: Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta. Biochem Biophys Res Commun 2005;338:717-722.
27. Brey RN: Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 2005;57:1266-1292.
28. Santelli E, Bankston LA, Leppla SH, and Liddington RC: Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004;430:905-908.
29. Streatfield SJ: Engineered chloroplasts as vaccine factories to combat bioterrorism. Trends Biotechnol 2006;24:339-342.
30. Horsch RB, Klee HJ, Stachel S, Winans SC, Nester EW, Rogers SG, and Fraley RT: Analysis of Agrobacterium tumefaciens virulence mutants in leaf discs. PNAS 1986;83:2571-2575.
31. Golovkin M, Spitsin S, Andrianov V, Smirnov Y, Xiao Y, Pogrebnyak N, Markley K, Brodzik R, Gleba Y, Isaacs SN, and Koprowski H: Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci USA 2007;104:6864-6869.
32. Kohl T, Hitzeroth II, Stewart D, Varsani A, Govan VA, Christensen ND, Williamson AL, and Rybicki EP: Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol 2006;13:845-853.
33. Kohl T, Hitzeroth II, Christensen ND, Rybicki EP: Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol 2007;7:56.
34. Outchkourov NS, Peters J, de Jong J, Rademakers W, and Jongsma MA: The promoter-terminator of chrysanthemum rbcS1 directs very high expression levels in plants. Planta 2003;216:1003-1012.
35. Pogrebnyak N, Golovkin M, Andrianov V, Spitsin S, Smirnov Y, Egolf R, and Koprowski H: Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine. PNAS 2005;102:9062-9067.
36. Milich DR, Schodel F, Hughes JL, Jones JE, and Peterson DL: The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997;71:2192-2201.
37. Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, and Rybicki EP: Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 2003;77:8386-8393.